Yew Bio-Pharm Group, Inc.
YEWB · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.02 | 0.07 | 0.06 |
| FCF Yield | -0.28% | -70.28% | -2.67% | -33.80% |
| EV / EBITDA | 5.63 | 10.01 | 0.90 | 4.62 |
| Quality | ||||
| ROIC | 4.42% | -1.17% | -11.50% | 6.44% |
| Gross Margin | 12.92% | 2.78% | 28.52% | 12.49% |
| Cash Conversion Ratio | 11.84 | 12.13 | -24.55 | -0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.11% | -11.73% | -9.87% | 11.09% |
| Free Cash Flow Growth | 99.41% | -718.34% | 90.25% | -688.00% |
| Safety | ||||
| Net Debt / EBITDA | 3.42 | 6.79 | 0.26 | 1.58 |
| Interest Coverage | 5.33 | -1.59 | 2.44 | 14.77 |
| Efficiency | ||||
| Inventory Turnover | 1,627.92 | 10.28 | 4.33 | 13.76 |
| Cash Conversion Cycle | -3.37 | 134.21 | 80.80 | 309.53 |